---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007300"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-09-23T12:00:14+00:00"
generated_at: "2026-09-23T12:05:28.432279+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Valion Bio appoints Dean Zikria as Interim CEO; board leadership reshuffled

## Summary
- Dean Zikria appointed Interim CEO effective Sept 22, 2026; he remains on the Board.
- Zikria earns $23,333/month, 50k RSUs (plus 50k more if plan enlarged), and potential cash bonus on strategic transaction.
- Sheryle Bolton resigned from Board Sept 17, 2026; Thomas Jensen named Board Chair and Compensation Committee Chair.
- Jared Malbin appointed Audit and Risk Committee Chair; Zikria removed from audit, comp, and governance committees.
- Company emphasizes advancing Entolimod and evaluating strategic, commercial, and government opportunities.

## SEC filing metadata
- accession: 0001683168-26-007300
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-09-23T12:00:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007300/0001683168-26-007300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007300/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007300
- JSON: https://secwatch.observer/filing/0001683168-26-007300.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.